Scan this code to subscribe!

03/15/2018

Author Timothy Hoff Discusses His Latest Work: "Next In Line: Lowered Care Expectations in the Age of Retail - and Value Based Health" (March 14th)

Listen Now

During this 29-minute interview, Professor Timothy Hoff discusses moreover what market factors explain or are driving the degradation of the therapeutic relationship between the physician and the patient, or what he terms the doctor-patient dyad, these include the "retailing" of medicine, whether "next in line" retail medicine, where we've traded relational trust for calculative trust, is economically rationale, the (negative) effect it is having on physicians and possible solutions to save the physician-patient relationship and raise care delivery expectations. 

Professor Timothy Hoff is Professor of Management, Healthcare Systems, and Health Policy in the D'Amore-McKim School of Business and School of Public Policy and Urban Affairs at Northeastern University.  He is also a Visiting Associate Fellow at Oxford University's Green-Templeton College and a Visiting Scholar at the Said Business School, Oxford University.  Prior to Hoffhis academic career, Dr. Hoff worked for a decade as a primary care practice administrator and as a healthcare consultant.  His research has been published in Pediatrics, Archives of Internal Medicine, Journal of Organizational Behavior, Academy of Management Perspectives, Health Affairs and The Milbank Quarterly.   His research has received rewards from the American Sociological Association, Academy of Management, and the Society for Applied Anthropology.  His previous work, Practice Under Pressure: Primary Care Physicians and Their Work in the 21st Century earned an Outstanding Academic Title award from Choice Magazine in 2010.  He is also co-editor of the 2016 reference volume on transformation in the health professions workforce, it's titled, The Healthcare Professional Workforce also published by Oxford University Press.  Professor Hoff received his undergraduate degree in business administration and his Ph.D. in Public Administration and Policy from the University of Albany.  

For information on Next In Line go to: https://global.oup.com/academic/product/next-in-line-9780190626341?cc=us&lang=en&.

 

03/11/2018

Author Jonathan Engel Discusses His Recent Work, "Unaffordable: American Healthcare From Johnson to Trump" (March 9th)

Listen Now

During this 30-minute interview Professor Engel discusses moreover why, as he notes, US healthcare is "uniquely dysfunctional," and "laden with profit taking" largely due to induced demand, provides an overview of efforts to contain spending growth via HMOs both in the commercial and the Medicare market, the success of Medicaid HMOs, and discusses his disappointments with the Affordable Care Act (ACA) actually making healthcare more affordable.    

Jonthan Engel is Professor of Health Policy and Management at the Marxe School of Public and International Affairs at Baruch College, CUNY.  He has taught previously at Seton Hall University, Mailman School of Public Health at Columbia University and the School of Public Health at the University of Massachusetts.  He has been a consultant to the White House's President's EngelJonathan-2017.165tAdvisory Committee on Human Radiation Experiments, the lead author on multiple HIV needs assessments for the City of Newark and director of research at the Local Area Board for Health Planning for Essex and Union counties in New Jersey.  His published works include: Doctors and Reformers: Discussion and Debate of Health Policy 1025-1950; Poor People's Medicine: Medicaid and the US Charity Care Since 1965; The Epidemic: A History of AIDS; American Therapy: The Rise of Psychotherapy in the US; and, Fat Nation, forthcoming.   He is currently writing a book on Cold War science and policy in the US.  Professor Engel received his BA from Harvard, an MBA from the Yale School of Management and his PhD in the history of medicine from Yale.  

For more information on "Unaffordable" go to: https://uwpress.wisc.edu/books/5682.htm.

03/04/2018

Unpacking BPCI, CMS' New Bundled Payment Demonstration: An Interview with Dave Terry (February 28th)

Listen Now

This past January 9th CMS announced Bundled Payment for Care Improvement (BPCI) Advanced.  This five-year Medicare bundled or episode-based payment demonstration, that begins this October 1st, will succeed the agency'a five-year BPCI demonstration that sunsets this September 30th.  BPCI Advanced, also voluntary, will be considerably less expansive than its predecessor in that, among other things, it will include just 32 clinical episodes (29 inpatient and three outpatient), and offer only a single, 90 day retrospective bundled payment under one risk track.

During this 28 minute interview Mr. Dave Terry briefly defines Archway's business model/s, posits what attributes describe successful bundled payment providers, summarizes the findings from a recent study, he coauthored, of BPCI reimbursed total hip arthroplasty surgeries, how CMS has improved bundled payments under BPCI Advanced, or moreover in financial benchmarking and in quality measurement, the legitimacy of criticisms regarding care fragmentation and competition with other pay for performance models and likely success of the demonstration.

Mr. Dave Terry is currently CEO of Archway Health.  Previously, at Partners Healthcare in Boston, Mr. Terry negotiated Terry  Daveglobal cap and pay for performance contracts with managed care plans.  Prior still at Harborside Healthcare, he led a home care agency that managed Medicare and commercial episodes of care within a single payment.  As a partner with The Chartis Group, Mr. Terry developed provider networks and risk sharing models for Medicare Accountable Care Organizations (ACOs).  Mr. Terry holds an MBA from the Harvard Business School and a BA from Columbia University.  He currently serves on the board of Bottom Line, a national educational non-profit, and is a past board member of the Harvard Business School Health Industry Alumni Association.

For information on BPCI Advanced to go: https://innovation.cms.gov/initiatives/bpci-advanced.

02/22/2018

The Trump Administration's Decision to Require Employment as a Medicaid Coverage Prerequisite: An Interview with Prof. Sara Rosenbaum (February 21st)

Listen Now

In a letter last March to state Medicaid directors by then DHHS Secretary Tom Price and CMS Administrator Seema Verma telegraph the administration's intent to radically redefine the Medicaid program.  Believing the ACA's expansion of the Medicaid program was, per the March letter, a "clear departure from the core, historical mission of the program,"  administration officials telegraphed they were preparing to reinvent the program by, in part, requiring work or community engagement for abled-body adults as a precondition for Medicaid coverage.  Historically, the Medicaid program was intended to strengthen and increase coverage for the poor.  In a nine-page, January 11 letter to state Medicaid directors, Ms. Verma announced, "a new policy to assist states in their efforts to improve Medicaid enrollee health and well-being through incentivizing work and community engagement."  That there is no evidence that work improves health status, the January 11th letter stated "work . . may improve health outcomes," on January 12th CMS approved a Kentucky waiver to require employment as a prerequisite for Medicaid coverage despite state officials recognizing through the course of the waiver's implementation 15 percent of abled-body Kentuckians would lose coverage.    

During this 20 minute interview, Professor Sara Rosenbaum briefly explains Medicaid 1115 waivers, the administration's intent to, in addition to requiring employment, refashion the Medicaid program to more resemble commercial insurance, what evidence the administration posits to justify the policy change, the details of the Kentucky waiver (the first of likely several, if not many work requirement waivers), the anticipated effects of the Kentucky waiver and the legal bases for litigation already filed to challenge the Kentucky waiver. 

Professor Sara Rosenbaum is the Harold and Jane Hirsh Professor of Health Law and Policy at the Milken Institute School of Public Heath at George Washington University.  She also holds professorships at GWU's Law and Medical Schoold and at the Sara%20Rosenbaum%20Color%20Pic[1]Trachtenberg Schoolf of Public Policy and Public Administration.  Professor Rosenberg worked in the Clinton Administration where she directed and drafted the Health Security Act and designed the Medicaid's Vaccines for Children program.  She currently advises states, foundations and others on health policy and has served as a testifying expert in landmark litigation to enforce children's rights under Medicaid.  She is the lead author of Law and the American Health Care System.  Professor Rosenbaum is the Past Chair of AcademyHealth and a member of the National Academies of Sciences, Engineering, and Medicine.  She also has served on the CDC's Director's Advisory Committee and Advisory Committee on Immunization Practice.  She was the founding Commissioner of the Congress's Medicaid and CHIP Payment and Access Commission (MACPAC) and served as its Chair from January 2016 through April 2017.

Recent related writings by Professor Rosenbaum, i.e., "The Trump Administration Re-Imagines Section 1115 Medicaid Demonstration - and Medicaid" (Health Affairs Blog, 11/9/17) and "Experimenting on The Health of the Poor: Inside Stewart v. Azar (Health Affairs Blog, 2/5/18) are at: https://www.healthaffairs.org/do/10.1377/hblog20171109.297738/full/  and https://www.healthaffairs.org/do/10.1377/hblog20180204.524941/full/.

02/16/2018

Misuse of Antipsychotics Continues to Harm and Kill Thousands of Nursing Facility Residents: An Interview With Ms. Hannah Flamm (February 15th)

Listen Now

In early February the Human Rights Watch (HRW) published, "'They Want Docile': How Nursing Homes in the US Over-medicate People with Dementia."  The inappropriate or misuse of antipsychotics, e.g., Haldol, Seroquel and Risperdal, in nursing facilities to chemically restrain nursing home patients, moreover frail and elderly seniors, has been practiced for decades.  The HRW report found in 2016-2017 "massive use" or abuse, i.e., the report estimated in an average week over 179,000 long-stay nursing facility patients were administered antipsychotic drugs without a diagnosis for which the drugs are indicated or approved.  Despite efforts to reduce the abuse of these medications, in part via a CMS voluntary initiative (a link to which his provided below), the practice persists, in part, because the federal government has nominally enforced regulations and enforcement measures to remedy the problem.  The use of these drugs can and does cause serious patient harm.  In testimony before the Congress in 2007, the FDA's Dr. David Graham stated, "15,000 elderly people in nursing homes [are] dying each year form the off-label use of antipsychotic medications for an indication that the FDA knows the drug doesn't work."  Listeners may recall I initially discussed this topic in December 2012 with Diana Zuckerman.   

During this 36 minute discussion Ms. Flamm explains what prompted the HRW study, the study's methodology, how widespread is the practice of misuse of antipsychotics in nursing facilities, how and why they are used inappropriately, that includes the the failure to obtain free and informed consent, the federal government's inadequate enforcement of federal laws and regulations to police the problem and how this practice violates not just US laws but international human rights agreements. 

Ms. Hannah Flamm is currently an immigration lawyer at The Door's Legal Services Center in New York. FlammIn 2016-2017, Ms. Flamm was New York University's School of Law Fellow at Human Rights Watch where she researched and wrote, "They Want Docile."  She interned with the Southern Poverty Law Center, South Brooklyn Legal Services and Schonbrun DeSimone, an international human rights and civil rights firm.  She is a graduate of NYU's School of Law and the Harvard University Kennedy School of Government.  As a student she participated in NYU's Family Defense Clinic and the Harvard International Human Rights Clinic.  Prior to attending law school, Ms. Flamm worked for the International Rescue Committee in Haiti. 

The Human Rights Watch report is at: https://www.hrw.org/report/2018/02/05/they-want-docile/how-nursing-homes-united-states-overmedicate-people-dementia.

Two related 2012 and 2011 DHHS Office of the Inspector General reports are at: https://oig.hhs.gov/oei/reports/oei-07-08-00151.pdf and https://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf.
 

 

02/11/2018

Mitigating the Opioid Crisis Via Abuse Deterrent Prescribing Practices: An Interview with Dr. Steven Passik (February 9th)

Listen Now

Fatalities related opioid use now account for over two-thirds of all drug overdoses annually, over 60,000, in the US.  Approximately 115 Americans die every day from an opioid overdose.  This number represents a five-time increase over the past two decades.  Opioid-related fatalities have become so prevalent, according to the National Center for Health Statistics, they have caused a decrease in US life expectancy for the past two consecutive years.  (The last time life expectancy dropped was in 1993 due to the AIDS epidemic.)  While the amount of prescription opioids sold to pharmacies, hospitals and doctors has quadrupled in the recent past, Americans are reporting on reduction in the amount of pain they suffer.  (Ironically, we are over prescribed and under treated.)  To date the federal government's response to the epidemic has been poor although this past week, the Congress appropriated $6 billion, an amount experts believe beyond inadequate, over a two year period to address the crisis.   

During this 28 minute interview Dr. Passik discusses the numerous causes contributing to the opioid epidemic, policies and practices in pharmacology that may be contributing to the problem, strategies used in pharmaceutical prescribing, or in the use of abuse deterrent formulations, to reduce addiction or abuse and the role other reforms in the clinical practice setting and in reimbursement can play in reducing harm and opioid-related fatalities.  

Since 2017 Dr. Steven Passki is currently the Vice President of Scientific Affairs, Education and Policy at Collegium PassikPharmaceuticals.  Prior to joining Collegium, Dr. Passik was Director of Clinical Addiction and Education at Millennium Laboratories.  Prior still, he spent 25 years in academia and clinical care at Memorial Sloan Cancer Center, at the University of Kentucky and at Vanderbilt University.  His research has focused on the psychiatric aspects of cancer and non-cancer pain and symptom management and the interface of pain management and addiction.  He has served as on the editorial board of the Journal of Pain and Symptom Management and as a reviewer for multiple journals including The Clinical Journal of Pain.  He has been a member of several scientific and medical societies including the American Psychological Association and the American Society of Psychiatric Oncology/AIDS.  He has written extensively on the interface of pain management and addiction. He is a clinical psychologist and has areas of expertise include the general psychological aspects of cancer including palliative care and symptom management with an emphasis on pain, depression, nausea and fatigue.  Dr. Passki was named a fellow of Division 28 of the American Psychological Association (Psychopharmacology & Substance Abuse) and awarded a Mayday Fund Fellowship in Pain and Society. An author of more than 120 journal articles, 60 book chapters and 59 abstracts, he speaks nationally and internationally on pain, addiction and the pain/addiction interface.  Dr. Passik received his doctorate in clinical psychology from the New School of Social Research in New York City.

I noted during the interview Dr. Passik will be keynoting a DC-area abuse deterrent formulations meeting in March, information on the meeting is at: http://www.cbinet.com/conference/pc18298.

02/07/2018

"Global Risks Report: Davos, Trump and Climate Change," (February 6th)

President Trump again denied the reality of climate change while attending the recent Davos, Switzerland, confab.  He said, in part, ice caps are now "setting records."  In reality, Arctic Ocean ice hit a record low in 2017 and is declining faster than any time in over the past 1,500 years.  Since climate change was on the Davos agenda, the problem was discussed in the accompanying World Economic Forum's 2018 "Global Risks Report."   Beyond what the report found, it's worth noting, as I stated in this essay, ocean temperatures set a record in 2017.  (Oceans absorb over 90 percent of the heat trapped by greenhouse gasses.)  Ocean temperatures, measured in Joules, substantially exceeded 2015, the previous record year, by 1.51 x 10^22 Joules, or the amount of electrical energy China produces annually.

My essay, under the above title, summarizes what the report found and, again, notes the professional medical communities indifference to the ever increasing catastrophic consequences of global warming. 

The World Economic Forum's "Global Risks Report" is at: https://www.weforum.org/reports/the-global-risks-report-2018.  

My essay is at: http://thehealthcareblog.com/blog/2018/02/06/global-risk-report-davos-trump-and-climate-change/.

Please see also or again my November 13th essay titled, "As the World Burns" at: http://www.3quarksdaily.com/3quarksdaily/2017/11/as-the-world-burns-.html

01/30/2018

Will Trump's Global Gag Rule Lead to More Abortions and Maternal Deaths: An Interview with Jonathan Rucks (January 29th)

Listen Now

A year ago last week the President Trump signed an executive order reinstituting the so called global gag rule (more formally termed the Mexico City policy).  The policy was first implemented by President Reagan and has gone in and out of effect depending on whether a Republican or Democrat holds the White House.  The initial policy only applied to abortions, i.e., in order to obtain US family planning funding aid, not for profits or non-governmental organizations (NGOs) had to certify they would not use non-US funding, including private funding, to perform or promote (i.e., they are gagged) abortions overseas.  Beginning in 2001, the policy was expanded to cover other forms of contraception.  Under President Trump the policy was substantially expanded.  Under this administration's global gag rule, NGOs can neither use US family planning funding aid (at $575 million annually) nor any US global health funding aid (that totals $8.8 billion) even if it is used to prevent or treat other public health issues, for example, HIV or malaria, unless, again, the NGO certifies it is not using other funds in performing or promoting abortion as a method of family planning.         

During this 21 minute conversation, Jonathan Rucks briefly explains PAI's mission, the Trump administration's significant expansion of the global gag rule, what effects the global gag rule has had in the past and what expected results an expanded policy will have going forward, what work PAI is doing to address the current global gag rule and past and present efforts by the Congress to prohibit the implementation of the rule via executive order. 

Jonathan Rucks is the Senior Director of Advocacy at PAI (formerly the Population Action International) where he is Rucksresponsible for the development and management of advocacy strategies to inform and influence public policy in the US and overseas in moreover developing countries to increases support for sexual and reproductive health and rights.  Prior to PAI, Mr. Rucks worked for Pathfinder International, prior still he spent eight years working for Congressional Representative Jan Schakowsky (D-IL) and Representative Jim Oberstar  (D-MN).  Mr. Rucks holds a master's degree in Strategic Security Studies from the College of International Security Affairs at the National Defense University in Washington, DC.   

For information regarding PAI go to: pai.org

President Trump's January 23, 2017 global gag rule memorandum is at: https://www.whitehouse.gov/presidential-actions/presidential-memorandum-regarding-mexico-city-policy/.

 

   

12/26/2017

"Fixing MACRA Means Fixing The APM Pathway" (December 26th)

Per my last interview, here is my most recent essay, titled, "Fixing MACRA Means Fixing the APM Pathway," posted by The Health Care Blog (THCB) on December 18th:http://thehealthcareblog.com/blog/2017/12/18/fixing-macra-should-mean-fixing-the-apm-pathway/.  As you'll see I, along with my co-author, Dr. Scott Hines, argue MedPAC's interest in reinventing MIPS misses the forest for the trees. 

Happy Holidays.  

12/19/2017

Kristen O'Brien Discusses the Final 2018 MACRA Rule (December 18th)

Listen Now

This past November 16 CMS published the agency's final 2018 MACRA (Medicare Access and CHIP Reauthorization Act) rule (at 661 federal register pages).  MACRA, authorized in 2015, formulates how approximately 1.5 million Medicare Part B physicians and other eligible clinicians are reimbursed.  Annual MACRA proposed and final rule making is closely monitored since the law's MIPS (Merit-Based Incentive Payment System) and Advanced Payment Model (APM) pathway are the two formulas CMS uses to annually update Fee for Service Medicare Spending (Part A and Part B) and how eligible clinicians under Medicare Advantage (Part C) can participate in MACRA's payment updates or rewards.    

During this 24 minute conversation Ms. O'Brien discusses the MIPS two threshold exclusions, MIPS quality and cost components, the composite performance score (CPS), the Advanced APM (AAPM) pathway, the anticipated 2018 Medicare Advantage (MA) AAPM demonstration and criticisms of MACRA implementation, specifically MedPAC's.  

Ms. Kristen O'Brien serves as Counsel at the law firm, Olsson, Frank and Weeda (OFW), in their Health Industry and Regulatory O'Brien Practice.  Prior to OFW, she served as Senior Legislative Counsel with the American Medical Association and prior still worked in private practice.   Ms. O'Brien's experience also includes serving as professional staff for the Senate Finance Committee under Former Committee Chair, Senator Max Baucus (D-MT), where she worked on health and environmental issues as well as financial reform.  Ms. O'Brien received her J.D. cum laude from Georgetown University Law Center and her undergraduate from Cornell University that included study at the London School of Economics.

The 2018 final MACRA rule is at: https://www.federalregister.gov/documents/2017/11/16/2017-24067/medicare-program-cy-2018-updates-to-the-quality-payment-program-and-quality-payment-program-extreme.